Mexican neuroscientist identifies glutamate biomarker predicting schizophrenia treatment success
Dr. Camilo de la Fuente-Sandoval has developed a groundbreaking approach to schizophrenia treatment prediction using neuroimaging and comprehensive clinical care. His team's research reveals elevated glutamate levels in the associative striatum that normalize with effective antipsychotic treatment.